Table 1.
Changes in NREMS, REMS, EEG slow-wave activity, and EEG power during NREMS in postinjection hours 1–6 after BzATP injection
| BzATP |
|||
|---|---|---|---|
| 0.04 nmol | 0.4 nmol | 4 nmol | |
| Dark-onset administration | |||
| NREMS | |||
| Treatment | F(1,7) = 1.63 | F(1,7) = 34.3* | F(1,7) = 35.7* |
| Interaction | F(10,70) = 5.0* | F(10,70) = 4.0* | F(10,70) = 5.2* |
| REMS | |||
| Treatment | F(1,7) = 34.3* | F(1,7) = 5.5* | F(1,7) = 0.0 |
| Interaction | F(10,70) = 4.0* | F(10,70) = 4.1* | F(10,70) = 4.5* |
| EEG SWA | |||
| Treatment | F(1,7) = 5.3 | F(1,6) = 0.2 | F(1,7) = 0.1 |
| Interaction | F(10,70) = 0.3 | F(10,60) = 3.8* | F(10,70) = 3.2 |
| EEG power hours 1-6 | |||
| Treatment | F(1,140) = 2.6 | F(1,120) = 4.2 | F(1,140) = 0.6 |
| Interaction | F(19,140) = 5.5* | F(19,120) = 3.3* | F(19,140) = 2.5* |
| Light-onset administration | |||
| NREMS | |||
| Treatment | F(1,8) = 6.4* | F(1,6) = 29.9* | F(1,7) = 0.2 |
| Interaction | F(10,80) = 2.4* | F(10,60) = 2.2* | F(10,70) = 2.0* |
| REMS | |||
| Treatment | F(1,8) = 2.1 | F(1,6) = 0.3 | F(1,7) = 8.6* |
| Interaction | F(10,80) = 0.9 | F(10,60) = 4.4* | F(10,70) = 3.4* |
| EEG SWA | |||
| Treatment | F(1,8) = 3.5 | F(1,6) = 0.5 | F(1,7) = 6.6* |
| Interaction | F(10,80) = 2.7* | F(10,60) = 13.0* | F(10,70) = 11.9* |
| EEG power hours 1-6 | |||
| Treatment | F(1,8) = 4.7 | F(1,6) = 3.9 | F(1,7) = 105.8* |
| Interaction | F(19,152) = 3.0* | F(19,114) = 13.2* | F(19,133) = 13.2* |
Values are statistical results for changes in non-rapid eye movement sleep (NREMS), rapid eye movement sleep (REMS), electroencephalographic (EEG) slow-wave activity (EEG SWA), and EEG power during NREMS in postinjection hours 1–6 after 3 doses of 2′(3′)-O-(4-benzoylbenzoyl)adenosine 5′-triphosphate (BzATP) injected at dark or light onset.
*
Significant difference between baseline and treatment condition (P < 0.05).